Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 10/2016

01.10.2016 | Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space

verfasst von: Achilles Ntranos, Fred Lublin

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is one of the most diverse human diseases. Since its first description by Charcot in the nineteenth century, the diagnostic criteria, clinical course classification, and treatment goals for MS have been constantly revised and updated to improve diagnostic accuracy, physician communication, and clinical trial design. These changes have improved the clinical outcomes and quality of life for patients with the disease. Recent technological and research breakthroughs will almost certainly further change how we diagnose, classify, and treat MS in the future. In this review, we summarize the key events in the history of MS, explain the reasoning behind the current criteria for MS diagnosis, classification, and treatment, and provide suggestions for further improvements that will keep enhancing the clinical practice of MS.
Literatur
1.
Aktas O, Ullrich O, Infante-Duarte C, Nitsch R, Zipp F. Neuronal damage in brain inflammation. Arch Neurol. 2007;64:185–9.CrossRefPubMed
2.
Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, Brück W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain. 2008;131:1749–58.CrossRefPubMed
3.
Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478–89.CrossRefPubMed
4.
Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–69.CrossRefPubMed
5.
6.
Derwenskus J, Lublin FD. Future treatment approaches to multiple sclerosis. Handb Clin Neurol. 2014;122:563–77.CrossRefPubMed
7.
8.
Allison RS, Millar JH. Prevalence of disseminated sclerosis in Northern Ireland. Ulster Med J. 1954;23:1–27.PubMed
9.
Broman T, Bergmann L, Fog T, Gilland O, Hyllested K, Lindberg-Broman AM, et al. Aspects on classification methods in multiple sclerosis. Acta Neurol Scand Suppl. 1965;13 Pt 2:543–8.PubMed
10.
Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, Mcdowell F, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–68.CrossRefPubMed
11.
Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg. 2004;106:147–58.CrossRefPubMed
12.
Rose AS, Ellison GW, Myers LW, Tourtellotte WW. Criteria for the clinical diagnosis of multiple sclerosis. Neurology. 1976;26:20–2.CrossRefPubMed
13.
McDonald WI, Halliday AM. Diagnosis and classification of multiple sclerosis. Br Med Bull. 1977;33:4–9.PubMed
14.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227–31.CrossRefPubMed
15.
Izquierdo G, Hauw JJ, Lyon-Caen O, Marteau R, Escourolle R, Buge A, et al. Value of multiple sclerosis diagnostic criteria. 70 autopsy-confirmed cases. Arch Neurol. 1985;42:848–50.CrossRefPubMed
16.
Engell T. A clinico-pathoanatomical study of multiple sclerosis diagnosis. Acta Neurol Scand. 1988;78:39–44.CrossRefPubMed
17.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–7.CrossRefPubMed
18.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol. 2005;58:840–6. doi:10.​1002/​ana.​20703.
19.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. Wiley Subscription Services, Inc. A Wiley Company. 2011;69:292–302.
20.
Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6:677–86.CrossRefPubMed
21.
Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, et al. Application of the new Mcdonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol. 2002;52:47–53.CrossRefPubMed
22.
Pia SM. The Will Rogers phenomenon: the effect of different diagnostic criteria. J Neurol Sci Elsevier. 2009;287:S46–9.CrossRef
23.
Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64:428–33.CrossRefPubMed
24.
Frohman EM, Balcer LJ, Calabresi PA. Multiple sclerosis: can retinal imaging accurately detect optic neuritis? Nat Rev Neurol. 2010;6:125–6.CrossRefPubMed
25.
Calabrese M, De Stefano N, Atzori M, et al. DEtection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol. 2007;64:1416–22.CrossRefPubMed
26.
Calabrese M, Rocca MA, Atzori M, Mattisi I, Bernardi V, Favaretto A, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology. 2009;72:1330–6.CrossRefPubMed
27.
Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol. 2010;67:376–83.PubMed
28.
Filippi M, Rocca MA, Calabrese M, Sormani MP, Rinaldi F, Perini P, et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology. 2010;75:1988–94.CrossRefPubMed
29.
Harel A, Ceccarelli A, Farrell C, Fabian M, Howard J, Riley C, et al. Phase-sensitive inversion-recovery mri improves longitudinal cortical lesion detection in progressive MS. PLoS One. 2016;11:e0152180.CrossRefPubMedPubMedCentral
30.
Rocca MA, Agosta F, Sormani MP, Fernando K, Tintorè M, Korteweg T, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol. 2008;255:683–91.CrossRefPubMed
31.
Filippi M. In-vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques. J Neurol. 2001;248:1019–29.CrossRefPubMed
32.
33.
Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, Seraj H, et al. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol. 2009;217:95–101.CrossRefPubMed
34.
Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A. 2008;105:18889–94.CrossRefPubMedPubMedCentral
35.
Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. Martin DP, editor. PLoS One. Public Library of Science; 2009;4:e7440.
36.
Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367:115–23.CrossRefPubMed
37.
Granberg T, Martola J, Kristoffersen-Wiberg M, Aspelin P, Fredrikson S. Radiologically isolated syndrome—incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult Scler. 2013;19:271–80.CrossRefPubMed
38.
Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014;9:e90509.CrossRefPubMedPubMedCentral
39.
Lebrun. The radiologically isolated syndrome Le syndrome radiologique isole. Rev. Neurol. (Paris). 2015;171:698–706.
40.
Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72:800–5.CrossRefPubMed
41.
Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995;1:37–47.PubMed
42.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–11.CrossRefPubMed
43.•
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86. The new multiple scleroris clinical course classifications.CrossRefPubMedPubMedCentral
44.
IFN Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655–61.CrossRef
45.
Fred L. History of modern multiple sclerosis therapy. J Neurol. 2005;252:3–9.CrossRef
46.•
Imitola J, Racke MMK, LK F, CJ B, DL R, RA N, et al. Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis? JAMA Neurol. American Medical Association; 2014;72:22–4. A great review about the current treatment goals of multiple sclerosis therapy.
47.
Bevan CJ, Cree BAC, JK A, E H, G G, LRE-W K, et al. Disease activity free status. JAMA Neurol. American Medical Association; 2014;71:269.
48.
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60.CrossRefPubMed
49.
Trojano M. Multiple sclerosis: the evolving diagnostic criteria for multiple sclerosis. Nat Rev Neurol Nature Publishing Group. 2011;7:251–2.CrossRef
Metadaten
Titel
Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space
verfasst von
Achilles Ntranos
Fred Lublin
Publikationsdatum
01.10.2016
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 10/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0688-8

Weitere Artikel der Ausgabe 10/2016

Current Neurology and Neuroscience Reports 10/2016 Zur Ausgabe

Behavior (H Kirshner, Section Editor)

Psychiatric and Cognitive Effects of Deep Brain Stimulation for Parkinson’s Disease

Epilepsy (CW Bazil, Section Editor)

Recent Advances in Neonatal Seizures

Neuro-Ophthalmology (A Kawasaki, Section Editor)

Visual Cortex Plasticity Following Peripheral Damage To The Visual System: fMRI Evidence

Dementia (KS Marder, Section Editor)

The Impact of Dementia on Family Caregivers: What Is Research Teaching Us?

Genetics (V Bonifati, Section Editor)

Transcriptional Dynamics at Brain Enhancers: from Functional Specialization to Neurodegeneration

Critical Care (SA Mayer, Section Editor)

Post-Craniotomy Pain Management: Beyond Opioids

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise